- Home
- IBRX vs VAC Comparison
IBRX vs VAC Comparison
Compare IBRX & VAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- VAC
- Stock Information
- Founded
- IBRX 2014
- VAC 1984
- Country
- IBRX United States
- VAC United States
- Employees
- IBRX N/A
- VAC N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- VAC Real Estate
- Sector
- IBRX Health Care
- VAC Finance
- Exchange
- IBRX Nasdaq
- VAC Nasdaq
- Market Cap
- IBRX 2.4B
- VAC 2.7B
- IPO Year
- IBRX N/A
- VAC N/A
- Fundamental
- Price
- IBRX $4.49
- VAC $91.24
- Analyst Decision
- IBRX Buy
- VAC Buy
- Analyst Count
- IBRX 2
- VAC 10
- Target Price
- IBRX $17.38
- VAC $98.05
- AVG Volume (30 Days)
- IBRX 10.4M
- VAC 449.9K
- Earning Date
- IBRX 11-12-2024
- VAC 11-06-2024
- Dividend Yield
- IBRX N/A
- VAC 3.33%
- EPS Growth
- IBRX N/A
- VAC N/A
- EPS
- IBRX N/A
- VAC 5.26
- Revenue
- IBRX $7,332,000.00
- VAC $3,194,000,000.00
- Revenue This Year
- IBRX $1,563.18
- VAC $54.30
- Revenue Next Year
- IBRX $1,262.20
- VAC $4.79
- P/E Ratio
- IBRX N/A
- VAC $17.36
- Revenue Growth
- IBRX 1218.71
- VAC N/A
- 52 Week Low
- IBRX $3.10
- VAC $67.28
- 52 Week High
- IBRX $10.53
- VAC $108.57
- Technical
- Relative Strength Index (RSI)
- IBRX 46.07
- VAC 65.72
- Support Level
- IBRX $4.57
- VAC $77.02
- Resistance Level
- IBRX $5.08
- VAC $94.94
- Average True Range (ATR)
- IBRX 0.54
- VAC 3.15
- MACD
- IBRX -0.12
- VAC 0.90
- Stochastic Oscillator
- IBRX 3.16
- VAC 62.15
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
About VAC Marriott Vacations Worldwide Corporation
Marriott Vacations Worldwide Corp functions in the United States leisure industry. It owns and manages a cluster of resorts and accommodation facilities under trademarks like Marriott Vacation Club, Grand Residencies, and The Ritz-Carlton Destination Club predominantly in the United States. Some of its properties are also spread across Europe and Asia Pacific. Marriott's majority revenue components include the sale of vacation ownership products such as luxurious vacation packages. In addition, it offers purchase money financing to the end users of its core services. The company operates in two reportable segments: Vacation Ownership and Exchange & Third-Party Management. The majority of revenue is derived from the Vacation Ownership segment.